Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2051260093 Minoxidil Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
JPRN-jRCT2051260093 clinical trial report covering Minoxidil, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07664553 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664553 clinical trial report covering Elecoglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665437 Remibrutinib Hidradenitis Suppurativa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665437 clinical trial report covering Remibrutinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07669454 Nuvastatic Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07669454 clinical trial report covering Nuvastatic, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665450 Ramantamig Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665450 clinical trial report covering Ramantamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07665476 Cephalexin Cellulitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665476 clinical trial report covering Cephalexin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
CTR20262465 Icodextrin Kidney Failure, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262465 clinical trial report covering Icodextrin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
Latest Hotspot
8 min read
NCT07664852 Pramipexole Dihydrochloride Bipolar Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664852 clinical trial report covering Pramipexole Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
8 min read
IMD-1828 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
IMD-1828: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
8 min read
DFI-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
DFI-105: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
8 min read
Anti CD 19/22 CAR- T Cells(Medical Visual Systems) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Anti CD 19/22 CAR- T Cells(Medical Visual Systems): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.
Read →
8 min read
GVB-2001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
GVB-2001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
<
1
<<
1005
1006
1007
1008
1009
>>
2260
>